Parataxis Korea Inc (288330)

Currency in KRW
2,375
-110(-4.43%)
Closed·
288330 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
288330 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,2702,590
52 wk Range
6719,280
Key Statistics
Bid/Ask
2,370.00 / 2,375.00
Prev. Close
2,485
Open
2,575
Day's Range
2,270-2,590
52 wk Range
671-9,280
Volume
1.59M
Average Volume (3m)
4.79M
1-Year Change
-34.39%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
288330 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Parataxis Korea Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Parataxis Korea Inc Company Profile

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomwise to launch small molecule programs across various therapeutic areas using structure-based AI technology for drug discovery; the University of Colorado School of Medicine to explore the potential of BBT-877 for immuno-oncology; and the Emory University School of Medicine to explore combination therapy of BBT-877 for KRAS/P53 mutant NSCLC patients resistant to anti-PD-1 blockade. The company was formerly known as Bridge Biotherapeutics, Inc. and changed its name to Parataxis Korea, Inc. in August 2025. The company was founded in 2015 and is headquartered in Seongnam, South Korea.

Compare 288330 to Peers and Sector

Metrics to compare
288330
Peers
Sector
Relationship
P/E Ratio
−10.9x−6.7x−0.5x
PEG Ratio
−0.17−0.180.00
Price/Book
5.2x2.7x2.6x
Price / LTM Sales
17,597.0x5.3x3.2x
Upside (Analyst Target)
-0.0%38.8%
Fair Value Upside
Unlock16.9%5.4%Unlock

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-86.00 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

288330 Income Statement

FAQ

What Stock Exchange Does Parataxis Korea Trade On?

Parataxis Korea is listed and trades on the KOSDAQ stock exchange.

What Is the Stock Symbol for Parataxis Korea?

The stock symbol for Parataxis Korea is "288330."

What Is the Parataxis Korea Market Cap?

As of today, Parataxis Korea market cap is 196.70B.

What Is Parataxis Korea's Earnings Per Share (TTM)?

The Parataxis Korea EPS (TTM) is -368.16.

From a Technical Analysis Perspective, Is 288330 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Parataxis Korea Stock Split?

Parataxis Korea has split 2 times.

How Many Employees Does Parataxis Korea Have?

Parataxis Korea has 35 employees.

What is the current trading status of Parataxis Korea (288330)?

As of 31 Aug 2025, Parataxis Korea (288330) is trading at a price of 2,375, with a previous close of 2,485.00. The stock has fluctuated within a day range of 2,270 to 2,590, while its 52-week range spans from 671 to 9,280.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.